NAVB - Key will be the nature of the issue - which hopefully is disclosed in full in the CC. The unknown (right now anyway) is how long of a delay we will see in LS approval. That needs to be assessed after all the facts are out. Mgmnt will be very quick to re-assure that the FDA issue is "under control" - to be candid...not expecting anything else. This will pass, in some respects may make it more volitile for awhile and hence tradable. But credibility is going to take a hit IMO.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.